中国癌症杂志
中國癌癥雜誌
중국암증잡지
CHINA ONCOLOGY
2013年
8期
584-589
,共6页
人表皮生长因子受体过表达%新辅助化疗%靶向治疗%病理完全缓解
人錶皮生長因子受體過錶達%新輔助化療%靶嚮治療%病理完全緩解
인표피생장인자수체과표체%신보조화료%파향치료%병리완전완해
HER-2 overexpression%Neoadjuvant chemotherapy%Targeted therapy%pCR
人表皮生长因子受体(human epidermal growth factor receptor 2, HER-2)高表达被视为预后不良的重要预测因素，但随着抗HER-2靶向治疗药物曲妥珠单抗的问世以及化疗联合靶向治疗的应用，其预后逐步得到了改善。新辅助疗法因可作为“体内药敏”试验的特殊优势，成为早期可手术乳腺癌综合治疗的一种新的选择模式。近年来，新一代的抗HER-2靶向药物和治疗方法层出不穷，而在验证其疗效方面，新辅助疗法提供了一个重要的研究平台。现对HER-2过表达乳腺癌新辅助化疗的相关临床试验结果进行分析和解读，并对新近开展的多项针对HER-2过表达乳腺癌的新辅助靶向治疗研究作一综述。
人錶皮生長因子受體(human epidermal growth factor receptor 2, HER-2)高錶達被視為預後不良的重要預測因素，但隨著抗HER-2靶嚮治療藥物麯妥珠單抗的問世以及化療聯閤靶嚮治療的應用，其預後逐步得到瞭改善。新輔助療法因可作為“體內藥敏”試驗的特殊優勢，成為早期可手術乳腺癌綜閤治療的一種新的選擇模式。近年來，新一代的抗HER-2靶嚮藥物和治療方法層齣不窮，而在驗證其療效方麵，新輔助療法提供瞭一箇重要的研究平檯。現對HER-2過錶達乳腺癌新輔助化療的相關臨床試驗結果進行分析和解讀，併對新近開展的多項針對HER-2過錶達乳腺癌的新輔助靶嚮治療研究作一綜述。
인표피생장인자수체(human epidermal growth factor receptor 2, HER-2)고표체피시위예후불량적중요예측인소，단수착항HER-2파향치료약물곡타주단항적문세이급화료연합파향치료적응용，기예후축보득도료개선。신보조요법인가작위“체내약민”시험적특수우세，성위조기가수술유선암종합치료적일충신적선택모식。근년래，신일대적항HER-2파향약물화치료방법층출불궁，이재험증기료효방면，신보조요법제공료일개중요적연구평태。현대HER-2과표체유선암신보조화료적상관림상시험결과진행분석화해독，병대신근개전적다항침대HER-2과표체유선암적신보조파향치료연구작일종술。
The overexpression of human epidermal growth factor receptor 2 (HER-2) is generally considered as an signiifcant predictor of poor prognosis, but the outcome has been rewritten with the appearance and application of the HER-2 targeted monoclonal antibody trastuzumab and chemotherapy plus targeted therapy. For the superiority of acting as "in vivo susceptibility” test, neoadjuvant chemotherapy has become a new comprehensive treatment mode for operable breast cancer. And it has also provided an important approach to investigate the effectiveness of newly appeared targeted therapy. We focused more on reviewing and analyzing the results of clinical trials related to preoperation chemotherapy and the latest studies in HER-2 positive breast cancer in this article.
